Ventyx Biosciences, Inc. (VTYX)
NASDAQ: VTYX · Real-Time Price · USD
8.42
+1.05 (14.25%)
At close: Oct 30, 2025, 4:00 PM EDT
8.44
+0.02 (0.24%)
After-hours: Oct 30, 2025, 5:47 PM EDT
Ventyx Biosciences Employees
As of December 31, 2024, Ventyx Biosciences had 82 total employees, including 79 full-time and 3 part-time employees. The number of employees increased by 2 or 2.50% compared to the previous year.
Employees
82
Change (1Y)
2
Growth (1Y)
2.50%
Revenue / Employee
n/a
Profits / Employee
-$1,451,549
Market Cap
600.42M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 82 | 2 | 2.50% |
| Dec 31, 2023 | 80 | 21 | 35.59% |
| Dec 31, 2022 | 59 | 32 | 118.52% |
| Dec 31, 2021 | 27 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VTYX News
- 6 days ago - Ventyx Biosciences, Inc. (VTYX) Discusses Positive Phase II Results of VTX3232 in Obesity and Cardiovascular Risk Factors Transcript - Seeking Alpha
- 8 days ago - Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors - GlobeNewsWire
- 2 months ago - Ventyx Biosciences to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress - GlobeNewsWire
- 4 months ago - Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease - GlobeNewsWire
- 5 months ago - Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 6 months ago - Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress - GlobeNewsWire
- 7 months ago - Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists - GlobeNewsWire